Download FALCIPARUM MALARIA PowerPoint Presentation

Login   OR  Register

Share page


Home / Health & Wellness / Health & Wellness Presentations / FALCIPARUM MALARIA PowerPoint Presentation

FALCIPARUM MALARIA PowerPoint Presentation

worldwideweb By : worldwideweb

On : Aug 07, 2014

In : Health & Wellness

Embed :

Login / Signup - with account for

  • → Make favorite
  • → Flag as inappropriate
  • → Download Presentation
  • → Share Presentation
  • Slide 2 - MALARIA Basic considerations and clinical features Malaria in man is caused by four distinct speciesofmalaria parasite: * P.vivax,P.falciparum,P.malariae,P.ovale * P.Vivax & P.falciparum are resposible for most of the infections found throughout the malarial belt. *P.malariae is widely distributed but is less common. *P.ovale is rare but in West Africa it seems to have replaced P.vivax. *Malaria is estimated to kill between 1.5 and 2.7 million people each year. *In an average one person, often a child below 5yrs. Of age die in every 12 seconds. *Additional 300-500 million people contact the disease each year(Butlon,1997)
  • Slide 3 - MALARIA MILESTONES 1600 B.C. References can be found in the writings 400 Hippocrates’ description of malaria.Charaka and Sushrutha gave vivid descriptions of malaria & even associated it with the bites of the mosquitoes. 1640 A.D. Huan del Vego – Cinchona bark for malaria treatment 1696 Morton first detailed picture of Malaria. 1717 Lanicsi Links malaria to bad air in swamps and thus originates the name malaria. 1816 Gize-Extraction of quinine from cinchona bark 1820 Pelletier and Caventou – extraction of pure quinine alkaloids 1880 Laveran identifies malarial parasite under microscope. 1895 Golgi-Identification of P.vivax & P.malariae 1889-90 Sakharov,Marchiafava,Celli-identification of P.falciparum cont…….
  • Slide 4 - 1897 Ronald Ross–Demonstration on malarial oocysts in gut of female anopheles mosquito 1934 Chloroquine synthesized by Germans. 1939 Paul Miller – Insecticidal properties of DDT 1944 Curd, Davey, Rose – Synthesis of Proguanil for treatment. 1950 Elderfield– Synthesis of primaquine. 1967 WHO- emphasis on control of malaria rather than global eradication of the disease. 1990’s Synthesis of quinine analogue mefloquine. Artemesinins obtained from Quinghaosu introduced for resistant malaria. 1994 Sequencing of P.Falciparum Genome begun 1999 WHO Recommends – Combined therapy to delay resistance development to anti-malarials Including Artemesinin. 2000 Chloroquine resistance gene identified as PfeRTK767
  • Slide 5 - PLASMODIUM VIVAX 1. Red cells containing parasites are usually enlarged. 2. Schuffner”s dots are frequently present in the red cells as shown. 3. The mature ring forms tend to be large and coarse. 4. Developing forms are frequently present. PLASMODIUM FALCIPARUM 1. Red cells are not enlarged. 2. Rings appear fine and delicate & there maybe several in one cell. 3. It is unusual to see developing forms in peripheral blood films. 4. Gametocytes have a characteristic crescent shape appearance.
  • Slide 6 - PLASMODIUM MALARIAE 1.Ring forms may have a squarish appearance. 2.Band forms are a characteristic of this species. 3.Mature schizonts may have a typical daisy head appearance with up to ten merozoites. PLASMODIUM OVALE 1. Only found in Africa. 2. Red cells enlarged. 3. Comet forms common. 4. Rings large and coarser.
  • Slide 7 - MALARIA PATHOLOGY * * Pigmentation of various organs with haemozoin giving a characteristic “SLATE GREY” Or “BLACK COLOUR”. * * Hyperplasia of the Reticulo-Endothelial system resulting from increased activity in order to deal with parasite and their product. * * Parasitized erythrocytes filling the Lumina of the capillaries of the internal organs. This is particularly seen in P.falciparum infection. * * Vascular changes-dilatation of sinusoidal vessels, perivascular haemorrhages are seen in falciparum malaria. * * Degenerative changes of parenchyma cells due to hypoxia [ seen in falciparum malaria]. * * Effects of anaemia. * * Immunosupression has been observed in malarial infection and this may lead to secondary bacterial infection.
  • Slide 8 - THE SPLEEN Spleen is enlarged,colour varies from slate gray to black, capsule is thin & stretched, consistency soft in acute cases while firm in chronic cases. “AGUE CAKE SPLEEN” THE LIVER The Liver is uniformly enlarged due to vascular congestion and proliferation of reticuloendothelial cells. The colour varies from chocolate red to slate gray or even black depending upon the stage of congestion and deposition of the haemozoin pigment. BONE MARROW KIDNEYS
  • Slide 9 - Does the Patient Need Hospitalization ? Seriously ill patients needing Hospitalization- Include:- Continuous vomiting andinability to retain oval drugs. Increasing Headache. Severe Dehydration. Poor general condition. Alteration of sensorium. Suspected cerebral malaria with unarousable Coma. Hyper pyrexia, convulsion. Pregnancy Oedema. Bleeding disorders.
  • Slide 10 - COMPLICATIONS : Cerebral malaria and coma. Hyperpyrexia. Haemolytic Anaemia. Non cardiogenic pulmonary oedema (ARDS ) ; Acute tubular necrosis and renal failure ; Acute Hepatomegaly and centrilobular necrosis ; Hypoglycaemia ; An adrenal insufficiency like syndrome ; Cardiac dysrhythmias ; Lactic acidosis .
  • Slide 11 - Pathophysiology : of complicated malaria Pathology associated with all malarial species is related to the rupture of the infected RBC and release of haemozoin (Malarial pigment). An increased in reticulo-endothelial system is fond causing hepato-splenomegaly. Cytoadhence of infected red cells to the vascular endothelium & RBC’s causing rossetting-compromises microcirculatory flow. In cerebral malaria-due to sequestration of the infected erythrocyles in the cerebral microcirculation. Sequestration in cytiadherence of trophozoite and schizont infected erythrocytes to the endothelial cells of the deeper vascular beds of the vital organs-specially the brain,liver,gut,heart & placenta,
  • Slide 12 - Table 1= Anti-malarial Drug
  • Slide 13 - Contd…. Table 1:- Anti-malarial Drugs
  • Slide 14 - Contd.
  • Slide 15 - Contd….
  • Slide 16 - Treatment of Resistant Malaria (Uncomplicated Resistant) 1.Sulphadoxine-Pyrimethamine :- patients weighing >50kg. 3 tablets stat, patients weighing <50kg. 2 tablets stat, (provided patient has no sulpha allergy) + quinine 600mg TDS for 2 days. 2.Quinine 600mg TDS or Quinine sulphate 10mg/kg/8 hrly for 7 days + Doxycycline 100mg BD or Tetracycline 500 mg BD for 7 days. 3.Mefloquine 750 mg stat, followed by 750 mg after 6 hrs. (Pts. Weighing > 50 kg) or 500mg stat followed by 500mg after 6hrs. (Pts. Weighing < 50 kg.)
  • Slide 17 - Treatment of Resistant Malaria (Complicated Resistant) Ideally all patients with complicated should be hospitalized. Inj. Quinine IV slowly in Dextrose. Higher loading dose is preferred relative to maintenance dose. In patients requiring more than 48 hours parenteral therapy, reduce the maintenance dose by ½ rd. In presence of renal failure; quinine dose should be halved after 48 hours. Inj. Artemether 160mg IM, then 80mg daily for 4 days
  • Slide 18 - Artemether Dosage regimen
  • Slide 19 - Comparative Efficacy : In Cerebral Malaria
  • Slide 20 - Arteether Dosage Regimen
  • Slide 21 - Bulaquine : A New generation Anti-malarial drug Bulaquine a derivative of primaquine developed by the Central Drug research Institute in collaboration with W.H.O., Advantage :- Bulaquine has a biological activity against the tissue schizont forms of Plasmodium Vivax having :- a. A better therapeutic window. b. Lesser side effects, c. A better therapeutic index as compared to current treatment available.
  • Slide 22 - Mechanism of action of : Bulaquine In contrast to current Drugs, 8-Aminoquinolones are the only drug which act on the liver stage and prevent infection by killing liver stages of the parasite before merozoites reach blood Stream. Thus prevents emergence of either primary or secondary attacks. Bulaquine Inhibits protein synthesis in protozoa and indirectly inhibits Polymerisation of Amino acids by the Plasmodia. It has also high gametocidal action.
  • Slide 23 - Dosage of Bulaquine :- ** 25 mg once daily for 5 days. ** Should be given with chloroquine for complete cure of Vivax malaria. INDICATION : For the treatment of Vivax malaria Contra-indications: 1. Rheumatoid Arthritis. 2. Systematic Lupus erythematosus. Concurrent use of Drugs known to cause Haemolysis
  • Slide 24 - Future of Malarial Treatment I. Gene Therapy. II. Malarial Vaccine. III. Genetic Mapping Plasmodium falciparum. IV. Low Interleukin-12 Activity in severe Plasmodium falciparum malaria.
  • Slide 25 - THANK YOU
Dieting Free PowerPoint Template


Views : 391

Virtual Identity Free PowerPoint Template

Virtual Identity

Views : 426

DNA Free PowerPoint Template


Views : 463

Obesity Free PowerPoint Template


Views : 745

Credit Debit Card Free PowerPoint Template

Credit Debit Card

Views : 412

Easter Eggs Free PowerPoint Template

Easter Eggs

Views : 618

Question Free PowerPoint Template


Views : 510

Smoking Free PowerPoint Template


Views : 450

Statistics and Graph Free PowerPoint Template

Statistics and Graph

Views : 645

Social Media Words Free PowerPoint Template

Social Media Words

Views : 408

Email Symbol Free PowerPoint Template

Email Symbol

Views : 456

Success Achievement Free PowerPoint Template

Success Achievement

Views : 460

Whilte Tulip Free PowerPoint Template

Whilte Tulip

Views : 490

Lab Equipment Free PowerPoint Template

Lab Equipment

Views : 451

Health Tips Free PowerPoint Template

Health Tips

Views : 1025

Back to School Free PowerPoint Template

Back to School

Views : 493

Coffee Free PowerPoint Template


Views : 818

Guitar Free PowerPoint Template


Views : 884

Yoga Free PowerPoint Template


Views : 2341

Yoga Meditation Free PowerPoint Template

Yoga Meditation

Views : 741

Description : Available FALCIPARUM MALARIA powerpoint presentation for free download which is uploaded by steve an active user in belonging ppt presentation Health & Wellness category.


Shortcode : Get Shareable link